Surrozen, Inc.
A clinical-stage biotech that turns the body's own repair signals into medicines, Surrozen builds antibody drugs that mimic Wnt proteins — the natural molecules that tell tissue to regenerate. Founded in 2015 by Stanford and other scientists, its lead work targets sight-threatening eye diseases like wet age-related macular degeneration. The name blends "surrogate" and "zen": the engineered antibodies act as stand-ins for the body's repair messengers, long considered impossible to turn into drugs.
Bought 65.6K
Bought 610.8K
Bought 1.39M
Bought 199.1K
Bought 193.5K
Granted 15.6K · Sold 3.5K
Granted 18.8K · Bought 1.5K · Sold 4.8K
Granted 18.5K · Bought 1.5K · Sold 4.5K
Granted 607
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Svennilson Peter +6 co-filers10% owner · 12 transactions | — | 2.26M | — | 65.6K | — |
| Kutzkey TimDirector, 10% owner · 20 transactions | — | 2.26M | — | 610.8K | — |
| Column Group III GP, LP +5 co-filers10% owner · 9 transactions | — | 2.20M | — | 1.39M | — |
| TCG Crossover Fund II, L.P. +3 co-filers10% owner · 20 transactions | — | 1.47M | — | 199.1K | — |
| Column Group III GP, LP +2 co-filers10% owner · 2 transactions | -93.3% | 616.5Kas of Apr 2024 | — | 193.5K | — |
| Li YangExec. Vice President, Research · 12 transactions | — | 20.3K | 15.6K | — | 3.5K |
| Williams Charles OChief Operating Officer · 12 transactions | -47.3% | 18.2K | 18.8K | 1.5K | 4.8K |
| Parker Craig CChief Executive Officer, Director · 8 transactions | -47.4% | 18.2K | 18.5K | 1.5K | 4.5K |
| Maleki Andrew PedrumChief Financial Officer · 1 transaction | — | 607 | 607 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +2.45M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.